Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296
Éric Rondeau, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, Stephan Ortiz, Eugene Swenson, Marc Vallée, Sung‐Soo Yoon, David Kavanagh, Hermann Haller, Sunil Babu, Nilüfer Broeders, Nicole Lietar, Fiona G. Brown, Philip Campbell, Josep M. Campistol, Miquel Blasco, Paramit Chowdhury, Theo Kasimatis, Lino Cirami, Leonardo Caroti, Guilia Antognoli, Yahsou Delmas, Vladimir Dobronravov, Anja Gaeckler, Cyril Garrouste, Gregory Greenwood, Siân Griffin, Chiu-Ching Huang, I−Ru Chen, Susan S. Huang, Jin Seok Kim, Gaetano La Manna, Giorgia Comai, Maria Cappuccilli, Moglie Le Quintrec, Guillaume Jeantet, Iino Fumie, Yosu Luque, Jan Menne, J Morelle, Éric Goffin, Anja Mühlfeld, Shashi Nagaraj, Gowthami M. Arepally, Doyeun Oh, Masayoshi Okumi, Manuel Praga Terente, Elena Gutiérrez, Paola Rodrı́guez, François Provôt, Ulf Schönermarck, Michael Fischereder, Natàlia Ramos Terrada, Barbara Seitz‐Polski, Guillaume Favrè, Sonia Boyer‐Suavet, Maria Vinogradova, Tatiana Kirsanova, Edwin Wong
Cited by 3Open Access
Abstract
The authors regret that 2 investigators were not included in the 311 Study Group. Members of the 311 Study Group are listed in the Appendix. The authors would like to apologize for any inconvenience caused.
Related Papers
No related papers found
Powered by citation graph analysis